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Objectives: Incremental health care resource utilization associated with autoso-
mal dominant polycystic kidney disease (ADPKD) was estimated across two sub-
groups; individuals with ADPKD and end-stage renal disease (ESRD) and those with 
ADPKD but without ESRD. MethOds: Study data were from a large administrative 
claims and enrollment database. Individuals 18 y/o or older, enrolled in tracked 
health plans for 12 months from April 1, 2011 through March 31, 2012, and with an 
ICD-9-CM diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or 
for “polycystic kidney, unspecified type (753.12) were identified as having ADPKD, 
and linked one-to-one with individuals without ADPKD on age and gender. ESRD 
was identified by presence of ICD-9-CM code 585.6. Zero-inflated negative bino-
mial models estimated incremental hospitalizations, hospital days, outpatient 
visits, and emergency room visits for each sub-group, adjusting for age, gender, 
Charlson co-morbidity index, cardiovascular disease, diabetes and geographical 
region. Results: A total of 3,844 individuals with ADPKD who satisfied selection 
criteria were linked one-to-one with 3,844 individuals without ADPKD. Among per-
sons with ADPKD, 644 had a diagnosis of ESRD. The sample was 53% female and 
55% were between 45 to 64 years old. Incremental mean (standard error) resource 
utilization associated with ADPKD with ESRD as compared to persons without 
ADPKD was 0.35 (0.052) or 35 additional hospitalizations per 100 patients, 2.5 (0.42) 
or 250 hospital days per 100 patients, and 24.0 (1.2) or 2,400 outpatient visits per 100 
patients. Incremental mean (standard error) resource utilization associated with 
ADPKD but without ESRD as compared to persons without ADPKD was 0.065 (0.028) 
or 6.5 additional hospitalizations per 100 patients, 0.5 (0.091) or 50 hospital days per 
100 patients, and 4.4 (0.41) or 440 outpatient visits per 100 patients. cOnclusiOns: 
ADPKD was associated with incrementally greater health care resource utilization 
even before patients reached ESRD.
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Objectives: This study evaluated treatment patterns and costs among patients 
with pancreatic cancer (PC). MethOds: A retrospective study analyzed data span-
ning January 2008-June 2012 from 3 large integrated claims databases. Adult patients 
with a diagnosis of PC (ICD-9 157.xx) were included if they had a minimum eligibility 
of 12 months prior and 3 months following their first PC diagnosis and had no diag-
nosis of cancer in the pre-period. Patients were categorized as having exocrine PC 
(ICD-9 157.0-157.3; 157.8-157.9), endocrine PC (ICD-9 157.4), or metastatic-exocrine 
PC (ICD-9 157.0-157.3; 157.8-157.9, 196.xx-199.xx). Treatment patterns, health care 
resource use, and all-cause costs (2012 USD) were evaluated after cancer diagno-
sis. Results: There were 2901, 6119, and 464 patients in each of the 3 databases 
meeting all inclusion criteria, respectively. The majority of patients had exocrine PC 
(97%-98%), with 40%-76% having metastatic disease. Patients were on average 60.3-
64.5 (±11.3-14.0) years of age and 43%-52% were female. No treatment was received 
by 35%-55% of patients, 36%-55% of patients received chemotherapy ± radiation 
and/or surgery, and 9%-10% received radiation and/or surgery without chemother-
apy. Second and third-line chemotherapy was received by 17%-32% and 9%-17% 
of patients, respectively. Among those with exocrine PC, patients with metastatic 
disease experienced an average of 0.25-0.31 inpatient, 2.3-2.9 office, 3.0-4.0 other 
outpatient visits and received 4.2-5.1 prescriptions per month vs 0.09-0.11 inpatient 
visits, 1.3-1.7 office visits, 1.3-1.9 other outpatient visits and 3.2-4.1 prescriptions per 
month in those without metastatic disease. Total monthly costs averaged $9,478-
$12,042 and $1,022-$3,084 in patients with and without metastatic disease, respec-
tively. The majority of costs were attributable to medical services ($7,977-$11,212 and 
$697-$2,852, respectively), with pharmacy costs contributing to a small proportion 
of the total costs ($830-$1,501 and $232-$326, respectively). cOnclusiOns: Health 
care resource utilization and costs are highest among those with metastatic PC, 
totaling as much as $12,042 per month.
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Objectives: In 2013 a change in WHO guidelines increased the number of people 
recommended to start antiretroviral treatment (ARVs) from 16 to 28 million world-
wide; at present around 10 million are enrolled in care. Additionally the number 
of people requiring second line antiretrovirals (ARVs) is increasing. Much of this 
burden is in Sub Saharan Africa (SSA). The Infectious Diseases Institute (IDI) in 
Kampala, Uganda runs a clinic of 8000 patients; some of these have been on ARVs 
for > 10 years. The objective of this study was to analyze actual costs of different 
patient subgroups per year at IDI. MethOds: We use a fully digitalized electronic 
patient management system (ICEA), which records individual patient data includ-
ing all visit information. We linked ICEA to Navision accountancy software, in order 
to determine the actual cost of patient care from October 2012-October 2013. The 
analysis was conducted from a provider perspective. We calculated the average cost 
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Objectives: Estimate direct medical costs of selected acute complications in 
patients with non-valvular atrial fibrillation (NVAF) at the Social Security (EsSalud) 
in Peru. MethOds: The electronic database of EsSalud´s reference hospital: Hospital 
Nacional Guillermo Almenara Irigoyen (HNGAI) was used to identify the study popu-
lation. International Classification of Diseases (ICD) 10 codes were used to identify 
patients with NVAF and select complications of AF. Complications of interest are: 
ischemic stroke, hemorrhagic stroke, systemic embolism and myocardial infarction. 
Stroke events were classified by severity as mild, moderate, severe or fatal. All cases 
from 2011 -2012 meeting the inclusion criteria were reviewed. Patient level data from 
clinical charts was extracted to estimate resource utilization per patient per event. 
Costs were estimated using EsSalud´s 2013 tariffs manual and expressed per patient 
in 2013 USD. Results: Ischemic stroke costs were estimated at $1,259, $1,818, $ 4,910, 
and $2,829.19 for mild, moderate, severe and fatal events, respectively. Hemmorhagic 
stroke were estimated at $1,707, $2,419, $11,991 and $2,111 for mild, moderate, severe 
and fatal event, respectively. Systemic embolism and myocardial infarction were esti-
mated to cost $1,707 and $1,703 respectively. cOnclusiOns: For AF patients within 
EsSalud, hemorrhagic stroke costs are higher than those estimated for ischemic 
stroke. As expected, costs increase as the severity of the event increase. These cost 
estimates can be used as patient-level costs inputs for economic model analysis of 
AF and its complications, from the perspective of EsSalud in Peru.
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Objectives: To describe Health Care Pathway and cost evaluation of patients with 
osteoporosis. MethOds: From ARNO Observatory, an Italian population database 
which provides comprehensive data referred to patient as: drug prescription, hospi-
tal discharges, imaging, lab tests and diagnostic examination, we analyzed a cohort 
of 185.489 subjects with osteoporosis in year 2011. A group without osteoporosis, 
matched by age, gender and LHU was compared to estimate differences in health 
costs and burden of disease. Results: On a population of 5,313,167 over 40 years, 
we identified 185,489 patients treated with osteoporosis drugs (prevalence 3.5%). 
Prevalence rate is higher in female than male (6.1% vs 0.1%), modal value on 70-79 
years. The average yearly cost/patient is 2.329€ , 53% more than pair-matched group. 
This cost is due for 38.4% to drugs (31% specific drugs, 69% others), 42.8% to hos-
pitalization and 18.8% to lab tests and diagnostic examinations. Most common 
specific drugs are bisphosphonates (81%), strontium ranelatum (21%), parathy-
roid hormone (1.2%) and SERMs (0.9%). A considerable percentage (24.8%) did not 
received vitamin D supplements in association. Compared to control group, patients 
with osteoporosis received more drugs expression of higher comorbidity (corticos-
teroids +70%, nervous system drugs +42%, PPI +33%) and were more frequently 
hospitalized, beyond fractures, for arthritis (+99%, p< 0.01) and chronic bronchitis 
(+52%, p< 0.01). Less than 50% of patients controlled their serum calcium levels in 
the last three years, 32% performed a densitometry and less than a fifth a radiog-
raphy. cOnclusiOns: A big data infrastructure is a valid instrument to evaluate 
patient care pathways, monitor the good practice of treatment and estimate cost 
of illness. In a large community setting of osteoporotic patients, the lack of supple-
ment of vitamin D undermines the effectiveness of the specific pharmacological 
treatment. Despite low diagnostic approach, patients cost as much to the National 
Health System especially due to their frequent co-morbidities.
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Objectives: Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), and 
Psoriatic Arthritis (PA) are rheumatic diseases which destroy articulations and limit 
their functions. The evolution of these conditions cause important physical impair-
ment, which leads to disability, work loss, self-sufficiency, and QoL deterioration, 
among others. The objective is to estimate the economic impact of three rheumatic 
diseases: Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis 
during 2011 using registries of the main Social Security Institution in the country 
called Instituto Mexicano del Seguro Social (IMSS). MethOds: It was review all 
registries related to the indications mentioned at different settings of care: ambula-
tory visits to GP and specialist, emergency room (ER), and hospital discharge (HD) 
of IMSS from January 1st to December 31st, 2011. Based on this information it was 
calculated the cost of care using unitary cost published by the Institution according 
to the type of service and the hospital DRG implicated. Results: In 2011 the IMSS 
provided 45,528 consultations for AS, 51% were for patients between 30-49 years-old. 
28,716 (63%) were for GP; 16,257 (36%) specialist; 555 (1%) ER, and 91 HD. For JIA, there 
were 6,285 consultations; 1,766 (28%) were for GP; 4326 (69%) for specialist; 193 (3%) 
ER, and 103 HD. For PA there were 1,587 consultations; 619 (39%) for GP; 873 (55%) 
specialist; 95 (6%) ER, and 195 HD. The costs of the three diseases at IMSS during 
2011 were: AS = US $2.94 million, JIA = US $0.68 million and PA= US $0.37 million. 
The total cost of the three was US $4 millions (ER 1US= 13MXN). cOnclusiOns: 
These diseases affect quality of life and ability to work, considerably. Therefore, the 
cost of the three diseases might be underestimated due to productivity loss which 
is not included in the cost.
